Research programme: cancer vaccines - Boehringer Ingelheim/Enara Bio
Latest Information Update: 10 Jan 2024
Price :
$50 *
At a glance
- Originator Enara Bio
- Developer Boehringer Ingelheim; Enara Bio
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Gastrointestinal cancer; Lung cancer